// App-Quantinova.ai

FRI0340 : COMPARISON OF SECUKINUMAB VERSUS ADALIMUMAB EFFICACY ON SKIN OUTCOMES IN PSORIATIC ARTHRITIS: 52-WEEK RESULTS FROM THE EXCEED STUDY

Researchers

Presenter

  • A. B. Gottlieb

Principal Investigators

  • F. Behrens

  • P. Nash

  • J. F. Merola

  • K. Ding

  • P. Pellet

  • L. Pricop

  • I. Mcinnes

Medical Centers

  • Icahn School of Medicine at Mount Sinai Hospital - New York - United States of America

  • Rheumatology Department, University Hospital Goethe-University, Frankfurt, Germany

  • Griffith University, Nathan, Australia.

  • Brigham and Women's Hospital Heart and Vascular Center and Harvard Medical School, Boston, United States of America

  • Novartis Pharmaceuticals Corporation East Hanover NJ United States

  • Novartis AG, Basel, Switzerland

  • University of Glasgow, Glasgow, United Kingdom

Locations

  • United States

  • Germany

  • Australia

  • Switzerland

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Dermatology

  • Musculoskeletal

Disease

  • Psoriatic arthritis

Biomarkers

  • N/A

Drug/Treatment

  • secukinumab

  • Adalimumab

Outcome

  • N/A

Study Design

  • Randomized

  • Double Blind/Blinded

  • Superiority

  • Active Comparator

  • Multicenteric

  • Controlled

  • Parallel Group

Phase

  • III

Study Id's

  • NCT02745080

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved